The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Histone deacetylase inhibitors: discovery and development as anticancer agents
Abstract
Histone deacetylase (HDAC) inhibitors are a new class of targeted anticancer agents. Several HDAC inhibitors are in clinical trials and have shown significant activity against a spectrum of both haematological and solid tumours at doses that are well tolerated by patients. HDACs and histone acetyltransferases can, by reversible acetylation, modify the structure and function of histones and proteins in transcription factor complexes, which are involved in the regulation of gene expression, as well as many non-histone proteins that are involved in regulating cell proliferation and cell death. HDAC inhibitors are a structurally diverse group of molecules; these agents selectively alter the expression of genes. HDAC inhibitors can induce cancer cell death, whereas normal cells are relatively resistant to HDAC inhibitor-induced cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Physiological functions of thioredoxin and thioredoxin reductase
Arnér, E. S. J., & Holmgren, A. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01701.x · Cited by 2,525
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“The expression of genes is largely regulated by the structure of chromatin (epigenetic gene regulation), which is a complex of DNA, histones and non-histone proteins [1-3].”
BackgroundSelf-citationStructures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Self-citationZhang, Y., & Reinberg, D. (2001) · Genes & Development · doi:10.1101/gad.927301 · Cited by 1,530
Kawaguchi, Y., Kovacs, J. J., McLaurin, A., Vance, J. M., Ito, A., & Yao, T.-P. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,524
The Sir2 Family of Protein Deacetylases
Blander, G., & Guarente, L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073651 · Cited by 1,495
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Histone and chromatin cross-talk
Fischle, W., Wang, Y., & Allis, C. D. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00013-9 · Cited by 1,207
HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor
Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153 · cited 15×
“KAWAGUCHI Y, KOVACS JJ, McLAURIN A et al.: The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress.”
BackgroundInfluentialFelsenfeld, G., & Groudine, M. (2003) · Nature · doi:10.1038/nature01411 · Cited by 1,150
Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Self-citationPPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs
He, T.-C., Chan, T. A., Vogelstein, B., & Kinzler, K. W. (1999) · Cell · doi:10.1016/s0092-8674(00)81664-5 · Cited by 1,085
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy
Zhang, C. L., McKinsey, T. A., Chang, S., Antos, C. L., Hill, J. A., & Olson, E. N. (2002) · Cell · doi:10.1016/s0092-8674(02)00861-9 · Cited by 973
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Self-citationKelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Self-citationHistone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis
Vega, R. B., Matsuda, K., Oh, J., Barbosa, A. C., Yang, X., Meadows, E., McAnally, J., Pomajzl, C., Shelton, J. M., Richardson, J. A., et al. (2004) · Cell · doi:10.1016/j.cell.2004.10.024 · Cited by 804
Three proteins define a class of human histone deacetylases related to yeast Hda1p
Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760
Gao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111871200 · Cited by 744 · cited 5×
“Class I HDACs play a role in cell death and proliferation pathways whereas class II HDACs appear to be important for tissue-specific functions [22-49].”
BackgroundInfluentialHDAC-6 interacts with and deacetylates tubulin and microtubules in vivo
Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., & Matthias, P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg115 · Cited by 740 · cited 4×
“HDAC6 [49] Mouse ES knockout ES cells Increase in α-tubulin acetylation”
BackgroundInfluentialStructural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710 · cited 1×
“Recently, the crystal structure of HDAC8–hydroxamate complex has been solved [69].”
BackgroundKhorasanizadeh, S. (2004) · Cell · doi:10.1016/s0092-8674(04)00044-3 · Cited by 674
Class II histone deacetylases: versatile regulators
Verdin, E., Dequiedt, F., & Kasler, H. G. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00073-8 · Cited by 664
(1996) · Europe PMC (PubMed Central) · Cited by 659
Binary switches and modification cassettes in histone biology and beyond
Fischle, W., Wang, Y., & David Allis, C. (2003) · Nature · doi:10.1038/nature02017 · Cited by 629
Chang, S., McKinsey, T. A., Zhang, C. L., Richardson, J. A., Hill, J. A., & Olson, E. N. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8467-8476.2004 · Cited by 613
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
Shao, Y., Gao, Z., Marks, P. A., & Jiang, X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408345102 · Cited by 605
Self-citationGrozinger, C. M., & Schreiber, S. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.140199597 · Cited by 588
Gui, C.-Y., Ngo, L., Xu, W. S., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550
Self-citationPeart, M. J., Smyth, G. K., van Laar, R. K., Bowtell, D. D., Richon, V. M., Marks, P. A., Holloway, A. J., & Johnstone, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500369102 · Cited by 539
Self-citationMitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536759100 · Cited by 531
Self-citationHistone Deacetylase Inhibitors
Miller, T. A., Witter, D. J., & Belvedere, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303094 · Cited by 530
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
Zhu, P., Martin, E., Mengwasser, J., Schlag, P., Janssen, K.-P., & Göttlicher, M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00114-x · Cited by 525
Butler, L. M., Zhou, X., Xu, W.-S., Scher, H. I., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182372299 · Cited by 510
Self-citationUpregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer
Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2004) · The Prostate · doi:10.1002/pros.20022 · Cited by 509
Ungerstedt, J. S., Sowa, Y., Xu, W.-S., Shao, Y., Dokmanovic, M., Perez, G., Ngo, L., Holmgren, A., Jiang, X., & Marks, P. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408732102 · Cited by 503
Self-citationAntioxidant Function of Thioredoxin and Glutaredoxin Systems
Holmgren, A. (2000) · Antioxidants & Redox Signaling · doi:10.1089/ars.2000.2.4-811 · Cited by 502
CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS
Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095825 · Cited by 494
Prospects: Histone deacetylase inhibitors
Dokmanovic, M., & Marks, P. A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20532 · Cited by 479
Self-citationHistone deacetylase inhibitors in cancer therapy
Johnstone, R. W., & Licht, J. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00165-x · Cited by 449
The role of the redox protein thioredoxin in cell growth and cancer
Powis, G., Mustacich, D., & Coon, A. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00313-0 · Cited by 443
Kao, H.-Y., Downes, M., Ordentlich, P., & Evans, R. M. (2000) · Genes & Development · doi:10.1101/gad.14.1.55 · Cited by 424
Histone Deacetylase Inhibitors
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91004-4 · Cited by 415
Pei, X.-Y., Dai, Y., & Grant, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0561 · Cited by 382
Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues
Choi, J., Kwon, H. J., Yoon, B., Kim, J., Han, S. U., Joo, H. J., & Kim, D. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb02153.x · Cited by 346
Regulation of histone deacetylase activities
Sengupta, N., & Seto, E. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20179 · Cited by 346
Kelly, W. K., & Marks, P. A. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0106 · Cited by 330
Self-citationGeorge, P., Bali, P., Annavarapu, S., Scuto, A., Fiskus, W., Guo, F., Sigua, C., Sondarva, G., Moscinski, L., Atadja, P., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3413 · Cited by 324
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
Fuino, L., Bali, P., Wittmann, S., Donapaty, S., Guo, F., Yamaguchi, H., Wang, H., Atadja, P. W., & Bhalla, K. N. (2003) · PubMed · Cited by 296
HDAC6 Expression Is Correlated with Better Survival in Breast Cancer
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Omoto, Y., Ando, Y., Mita, K., Hamaguchi, M., Hayashi, S.-I., & Iwase, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0455 · Cited by 293
Rosato, R. R., Almenara, J. A., Dai, Y., & Grant, S. (2003) · PubMed · Cited by 267
Kuendgen, A., Strupp, C., Aivado, M., Bernhardt, A., Hildebrandt, B., Haas, R., Germing, U., & Gattermann, N. (2004) · Blood · doi:10.1182/blood-2003-12-4333 · Cited by 255
Functional Domains of Histone Deacetylase-3
Yang, W.-M., Tsai, S.-C., Wen, Y.-D., Fejér, G., & Seto, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105993200 · Cited by 248
Histone deacetylase inhibitors: Understanding a new wave of anticancer agents
Villar‐Garea, A., & Esteller, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20372 · Cited by 247
Cloning and characterization of a histone deacetylase, HDAC9
Zhou, X., Marks, P. A., Rifkind, R. A., & Richon, V. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191375098 · Cited by 245
Self-citationRole of Class I and Class II histone deacetylases in carcinoma cells using siRNA
Glaser, K. B., Li, J., Staver, M. J., Wei, R.-Q., Albert, D. H., & Davidsen, S. K. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.043 · Cited by 218
Osada, H., Tatematsu, Y., Saito, H., Yatabe, Y., Mitsudomi, T., & Takahashi, T. (2004) · International Journal of Cancer · doi:10.1002/ijc.20395 · Cited by 213
Dequiedt, F., Kasler, H., Fischle, W., Kiermer, V., Weinstein, M., Herndier, B. G., & Verdin, E. (2003) · Immunity · doi:10.1016/s1074-7613(03)00109-2 · Cited by 212
Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation
(2002) · Advances in Cancer Research · doi:10.1016/s0065-230x(02)86002-x · Cited by 205
Guo, F., Sigua, C., Tao, J., Bali, P., George, P., Li, Y., Wittmann, S., Moscinski, L., Atadja, P., & Bhalla, K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2629 · Cited by 202
Rundlöf, A.-K., & Arnér, E. S. J. (2004) · Antioxidants & Redox Signaling · doi:10.1089/152308604771978336 · Cited by 195
Isolation and Characterization of Mammalian HDAC10, a Novel Histone Deacetylase
Kao, H.-Y., Lee, C.-H., Komarov, A., Han, C. C., & Evans, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108931200 · Cited by 193
Piekarz, R. L., Robey, R. W., Zhan, Z., Kayastha, G., Sayah, A., Abdeldaim, A. H., Torrico, S., & Bates, S. E. (2004) · Blood · doi:10.1182/blood-2003-09-3068 · Cited by 186
Scanlan, M. J., Welt, S., Gordon, C., Chen, Y., Gure, A. O., Stockert, E., Jungbluth, A. A., Ritter, G., Jäger, D., Jäger, E., et al. (2002) · PubMed · Cited by 180
A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Piekarz, R., & Bates, S. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383980 · Cited by 174
Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation and gene expression
Méjat, A., Ramond, F., Bassel-Duby, R., Khochbin, S., Olson, E. N., & Schaeffer, L. (2005) · Nature Neuroscience · doi:10.1038/nn1408 · Cited by 169
Histone-Deacetylase Inhibitors for the Treatment of Cancer
Lindemann, R. K., Gabrielli, B. G., & Johnstone, R. W. (2004) · Cell Cycle · doi:10.4161/cc.3.6.927 · Cited by 168
Mie Lee, Y., Kim, S.-H., Kim, H.-S., Jin Son, M., Nakajima, H., Jeong Kwon, H., & Kim, K.-W. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02787-0 · Cited by 165
Coffey, D. C., Kutko, M. C., Glick, R. D., Butler, L. M., Heller, G., Rifkind, R. A., Marks, P. A., Richon, V. M., & LaQuaglia, M. P. (2001) · PubMed · Cited by 154
Self-citationTumor cell‐specific cytotoxicity by targeting cell cycle checkpoints
Warrener, R., Beamish, H., Burgess, A., Waterhouse, N. J., Giles, N., Fairlie, D. P., & Gabrielli, B. G. (2003) · The FASEB Journal · doi:10.1096/fj.02-1003fje · Cited by 149
Spotswood, H. T., & Turner, B. M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16547 · Cited by 146
Waltregny, D., de Leval, L., Glénisson, W., Tran, S. L., North, B. J., Bellahcène, A., Weidle, U. H., Verdin, E. M., & Castronovo, V. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63320-2 · Cited by 145
Rascle, A., Johnston, J. A., & Amati, B. B. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.12.4162-4173.2003 · Cited by 145
Histone deacetylase inhibitors specifically kill nonproliferating tumour cells
Burgess, A., Ruefli, A. A., Beamish, H., Warrener, R., Saunders, N. A., Johnstone, R. W., & Gabrielli, B. G. (2004) · Oncogene · doi:10.1038/sj.onc.1207893 · Cited by 144
Park, J., Jung, Y., Kim, T. Y., Kim, S. G., Jong, H.-S., Lee, S. E., Kim, D.-K., Lee, J., Kim, N. K., Kim, T., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0709 · Cited by 143
From Discovery to the Coming Generation of Histone Deacetylase Inhibitors
Yoshida, M., Matsuyama, A., Komatsu, Y., & Nishino, N. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456602 · Cited by 124
Histone acetylation-mediated regulation of genes in leukaemic cells
Chambers, A., Banerjee, S., Chaplin, T., Dunne, J., Debernardi, S., Joel, S. P., & Young, B. D. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00072-8 · Cited by 123
Induction of Polyploidy by Histone Deacetylase Inhibitor: A Pathway for Antitumor Effects
Xu, W., Perez, G., Ngo, L., Gui, C.-Y., & Marks, P. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4608 · Cited by 121
Self-citationTou, L., Liu, Q., & Shivdasani, R. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3132-3139.2004 · Cited by 111
Role of histone deacetylase inhibitors in the treatment of cancer (Review)
Mei, S., Ho, A. D., & Mahlknecht, U. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.6.1509 · Cited by 109
Histone deacetylase inhibitors in clinical development
Rosato, R. R., & Grant, S. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.1.21 · Cited by 101
Takami, Y., & Nakayama, T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908066199 · Cited by 99
Li, X., Song, S., Liu, Y., Ko, S.-H., & Kao, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405179200 · Cited by 96
Acetylation of proteins as novel target for antitumor therapy: Review article
Gennaro, E. D., Bruzzese, F., Caraglia, M., Abruzzese, A., & Budillon, A. (2004) · Amino Acids · doi:10.1007/s00726-004-0087-3 · Cited by 94
Caspase-mediated Specific Cleavage of Human Histone Deacetylase 4
Liu, F., Dowling, M. L., Yang, X., & Kao, G. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402475200 · Cited by 93
Gray, S. G., Qian, C., Furge, K., Guo, X., & Teh, B. T. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.4.773 · Cited by 90
Yoshida, N., Omoto, Y., Inoue, A., Eguchi, H., Kobayashi, Y., Kurosumi, M., Saji, S., Suemasu, K., Okazaki, T., Nakachi, K., et al. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03239.x · Cited by 79
Histone Deacetylase Inhibitors: The Abbott Experience
Curtin, M. L., & Glaser, K. B. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456576 · Cited by 78
Jose, B., Oniki, Y., Kato, T., Nishino, N., Sumida, Y., & Yoshida, M. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.08.016 · Cited by 69
Huang, Y., Tan, M., Gosink, M. M., Wang, K., & Sun, Y. (2002) · PubMed · Cited by 57
Specific and Redundant Functions of Histone Deacetylases in Regulation of Cell Cycle and Apoptosis
Zhu, P., Huber, E., Kiefer, F., & Göttlicher, M. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1195 · Cited by 55
Yoshida, C., & Melo, J. V. (2004) · International Journal of Hematology · doi:10.1532/ijh97.04032 · Cited by 47
Takami, Y., Kikuchi, H., & Nakayama, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.23977 · Cited by 46
Blanchard, F., Kinzie, E., Wang, Y., Duplomb, L., Godard, A., Held, W. A., Asch, B. B., & Baumann, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205777 · Cited by 37
Shebzukhov, Y. V., Koroleva, E. P., Khlgatian, S. V., Belousov, P. V., Kuz'mina, K. E., Radko, B. V., Longpré, F., Lagarkova, M. A., Kadachigova, T. S., Гурова, О. В., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21240 · Cited by 19
Cloning and Characterization of the Murine Histone Deacetylase (HDAC3)
Mahlknecht, U., Hoelzer, D. F., Bucala, R., & Verdin, E. M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1389 · Cited by 14
Histone Deacetylase Inhibitors: Novel Targeted Anti-Cancer Agents
Marks, P. A., & Kelly, W. K. (2005) · Springer eBooks · doi:10.1007/1-4020-3642-6_12 · Cited by 3
Self-citation
Cited by
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
“The HDACi have shown synergistic or additive antitumor effects with a wide range of antitumor reagents, including chemotherapeutic drugs, new targeted therapeutic reagents and radiation, by various mechanisms, some unique for particular combinations (Rosato and Grant, 2004; Bhalla, 2005; Marks and Dokmanovic, 2005; Bo…”
BackgroundInfluentialSelf-citationMarks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Self-citationMultiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676
The Myc oncoprotein as a therapeutic target for human cancer
Vita, M., & Henriksson, M. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.015 · Cited by 552
Metadata
- Authors
- Marks, P. A., & Dokmanovic, M.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2005-11-25
- Volume
- 14
- Issue
- 12
- Pages
- 1497-1511
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2162438863
- Cited by
- 318
- References
- 101
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.